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and TCD-BM in absence of FLU (P  .01); recipient CMV
seronegative status (93% vs 69%, P  .02); HLA matched
donor-recipient pair (94% vs 69%, P  .01); negative transfu-
sion history (100% vs 83%, P  .05), and use of FLU in the
preparative regimen (94% vs 69% ,P  .01). Disease status at
HCT, androgen use, number of malformations, recipient age
and gender, mosaicism, and history of prior infections did not
have a demonstrable effect on neutrophil recovery. In multivar-
iate analysis, factors associated with improved neutrophil recov-
ery were CMV seronegative serostatus, HLA matched donor-
recipient pair and use of FLU (Table 1). Similarly, incidence of
platelet recovery (	20,000/uL) was signiﬁcantly higher in CMV
negative recipients (Relative Risk [RR] 2.46, 95% CI 1.16–5.22,
P  .02), HLA matched HSC (RR 3.1, 95% CI 1.39–6.82, P 
.01), and FLU (RR 10.8, 95% CI 2.82–41.3, P  .01). In
summary, hematopoietic recovery after AD HSCT in FA pa-
tients following FLU containing preparative regimens are com-
parable to those of HLA matched sibling donor BM recipients.
Therefore signiﬁcant practice changes should be considered
such as the use of a FLU containing preparative regimen,
particularly in the setting of TCD.
Table 1. Cox Regression on Primary Neutrophil Engraftment
Factors
Relative Risk
(95% CI) P-value
Model (X2  28.8, P < .01)
Recipient CMV
Positive* 1
Negative 1.95 (1.13–3.35) .02
HLA match
Mismatch* 1
Match 2.70 (1.59–4.60) .01
FLU
No* 1
Yes 2.10 (1.22–3.63) .01
*Note: reference category.
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LACK OF T CELL ALLOREACTIVITY TO CORD BLOOD MONONUCLEAR
CELLS
Chunduri, S., Mahmud, D., Abbasian, J., Rondelli, D. University of
Illinois at Chicago, Chicago, IL.
Transplantation of HLA-mismatched cord blood (CB) nucleated
cells has limited risk of graft rejection and severe acute graft-
versus-host disease. This may depend on naı¨ve T cells not yet
exposed to many antigens and/or on immature antigen-presenting
cells (APC) not delivering appropriate signals to allogeneic T cells.
In order to test the APC activity of human circulating CB cells in
vitro, we initially used irradiated CB mononuclear cells (MNC) or
immunomagnetically selected CD34 cells, CD133 cells, or
CD14 monocytes to stimulate the proliferative response of in-
compatible blood T cells in mixed leukocyte culture (MLC). CB
MNC failed to induce allogeneic T cell proliferation, while
CD34 and CD133 progenitors or CD14 monocytes induced
potent T cell alloresponses. Nevertheless, since allogeneic T cell
response was not restored after depletion of CD3 cells in the CB,
or the add-back of irradiated CB MNC to CD34 or CD14
stimulators inhibited allo-T cells, a direct suppressive effect of CB
MNC was excluded. Allogeneic peripheral blood cytotoxic T-
lymphocyte (CTL) responses were not induced after 7 days of
stimulation with irradiated CB MNC, although after 4 weekly
rechallenges with CB MNC, on average a 23% lysis of antigen-
speciﬁc CB PHA-blasts was observed at the highest effector:target
ratio (50:1). To test the tolerogenic potential of CB MNC, T cells
initially exposed to CB MNC were rechallenged in secondary
MLC with CB MNC, or CD34 cells, or monocyte-derived
dendritic cells (Mo-DC) generated in liquid culture with GM-CSF
and IL-4. Allogeneic T cells were still unresponsive upon rechal-
lenge with CB MNC, but proliferated upon 3 days of restimulation
with CD34 cells or Mo-DC from the same CB. These results
show an impaired allo-APC activity of CB MNC but not CB
CD34 cells, and suggest that although CB cells do not induce an
Ag-speciﬁc in vitro anergy, their weak APC activity may reduce the
risk of rejection in an HLA-mismatched stem cell transplant set-
ting. In addition, these ﬁndings may explain the initial engraftment
of two mismatched CB grafts, currently infused in CB transplant
protocols for adult patients.
206
NO ASSOCIATION BETWEEN MIC-A POLYMORPHISM AND CLINICAL
OUTCOME AFTER ALLOGENEIC HSCT
Uzunel, M., Remberger, M. Karolinska Institutet, Clinical Immunology,
Stockholm, Sweden.
Background: MHC class I chain related molecule A (MIC-A)
shows homology with the classical HLA molecules. MIC-A is
polymorphic with more than 50 recognized alleles and is described
as a “marker of stress” since it is up-regulated on epithelial cells at
heat and virus infection. The presence of MIC-A antibodies in
patient sera has been associated with rejection after organ trans-
plantation. The signiﬁcance of MIC-A polymorphism in hemato-
poietic stem cell transplantation (HSCT) has not been studied. In
this study we wanted to see the degree of MIC-A mismatch be-
tween patients and donors and to investigate if the MIC-A geno-
type was associated with clinical outcome after HSCT. Materials
and Methods: For MIC-A genotyping, we performed PCR am-
pliﬁcation with allele-speciﬁc primers. A total of 248 leukemia
patients were included in the study. All received myeloablative
conditioning and GVHD prophylaxis consisted mainly of a com-
bination of cyclosporine A and methotrexate. In unrelated trans-
plants (149), both the patient and the donor were genotyped while
in sibling transplants (99) only the patient was genotyped. Results:
In unrelated transplants, 16 (11%) mismatches were found. Al-
though an increase in the incidence of chronic GVHD was found
among patients receiving a graft with MIC-A mismatch, there were
no signiﬁcant differences in leukemia free survival (LFS), trans-
plant related mortality (TRM) and GVHD between patients with
MIC-A match or mismatch. At the MIC-A allele level, no speciﬁc
allele was found to be associated with different clinical outcomes
after HSCT. Conclusion: MIC-A mismatch is a rare event in
HLA matched HSCT. Neither the MIC-A mismatch nor the
MIC-A alleles seem to have a major effect on the clinical outcome
after HSCT.
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HSCT FROM PARTIALLY MATCHED ALTERNATIVE DONORS—A SINGLE
CENTRE EXPERIENCE
Vitek, A.1, Cetkovsky, P.1, Dobrovolna, M.1, Ivaskova, E.2,
Korinkova, P.1, Kovarova, P.1, Kupkova, L.2, Loudova, M.1,
Markova, M.1, Matejkova, E.1, Navratilova, J.3, Pitrova, H.3,
Pohlreich, D.1, Sajdova, J.1, Sponerova, D.1, Valkova, V.1, Vrana, M.1,
Vytiskova, J.1 1. Institute of Hematology and Blood Transfusion, Prague,
Czech Republic; 2. Czech Marrow Donor Registry, Prague, Czech Re-
public; 3. Czech National Marrow Donor Registry, Pilsen, Czech Re-
public.
Increased amount of indications for alloBMT is connected with
increased demand for donors. For approximately 30% of the pa-
tients is possible to ﬁnd HLA identical sibling, for another 70% of
the patients is necessary to obtain graft from alternative donors.
Because it can be difﬁcult or even impossible to ﬁnd fully matched
alternative donors, that means donors identical in all 10 HLA
antigens typed on HR level of A, B, C, DRB1, and DQB1 loci, we
must often accept donors with some mismatches. We performed
182 transplantations from alternative donors between 1991 and
2005. 89 were mismatched for one or more HLA alleles or anti-
gens. Twenty-nine patients were transplanted for AML, 26 for
CML, 12 for ALL, 10 for MDS, 4 for CLL, 3 for MMM, 2 for
NHL, 2 for HD, and 1 for MM. Half of these patients were
transplanted in advanced stage of the disease. In 80% of the
patients, ATG-Fresenius was used in conditioning and 17% of the
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patients were transplanted without serotherapy. The most frequent
mismatch in our cohort of the patients was single mismatch on C
locus (28%), followed by combined mismatch in class I and II
(24%). Multiple mismatch in class I was present in 19% and 1
single mismatch on A or B loci in 8% of the patients. Seven percent
of the patients received graft with 2 mismatches on C, while 7%
received graft with 1 and 7% with multiple mismatch in class II
HLA. Results: 34 patients developed GVHD (Gr I-38%, Gr
II-38%, Gr III-12%, and Gr IV-12%). Forty-one patients died
after BMT; 40% for relapse, 31% for infection, 18% for GVHD,
and 11% due to VOD. Three year probability of survival is 40%
for AML, 60% for CML, 75% for ALL, and 30% for MDS
patients. Three-year probability of survival of the 17 patients, 14 of
whom in advanced stage of the disease, who received graft mis-
matched for DRB1, is 50%. Summary: BMT from partially
matched alternative donors offer chance for the patients without
fully (10/10) matched donor. ATG in conditioning decreases the
risk of severe GVHD (24% Gr IIIIV). Relapse and infection
were the most common causes of treatment failure in our cohort of
the patients.
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A SYSTEMATIC REVIEW AND META ANALYSIS OF UNRELATED DONOR
UMBILICAL CORD BLOOD TRANSPLANTATION VERSUS UNRELATED
DONOR BONE MARROW TRANSPLANTATION IN ADULT AND PEDIAT-
RIC PATIENTS
Hwang, W.Y.K.1, Samuel, M.2, Tan, D.C.L.1, Koh, L.P.1, Linn, Y.C.1
1. Singapore General Hospital, SingHealth, Singapore, Singapore; 2.
Clinical Trials and Epidemiology Research Unit, Singapore, Singapore.
Several studies have been performed to compare the results of
unrelated donor bone marrow transplantation (UBMT) with un-
related donor cord blood transplantation (UCBT). In order to
objectively analyze these data, we performed a systematic review
and meta analysis of pooled data on comparative studies on unre-
lated donor BMT versus UCBT to evaluate if UCBT is equivalent
to BMT in patients requiring a haematopoietic stem cell trans-
plant. Combining the studies, 161 children and 331 adults under-
going UCBT (mostly 1-2 antigen mismatched), as well as 316
children and 646 adults undergoing UBMT (almost entirely fully
matched with the recipient) were analyzed. Post-transplant en-
graftment of neutrophils and platelets occurred slower and more
infrequently with UCBT, although the difference was only in the
order of 10–20%. Two to 3 year overall survival was equivalent in
children undergoing UCBT (35 to 59%) compared to those who
had matched unrelated donor BMT (41 to 57%). In pooled com-
parisons of the studies between UCBT and UBMT in children,
chronic graft-versus-host disease (GVHD) was less with UCBT
(pooled estimate 0.26, CI 0.12–0.57, P  .0007) although grade
III–IV acute GVHD (pooled estimate1.46, CI 0.42–5.03) was no
different. There was a trend towards lower overall mortality in
children undergoing UCBT (pooled estimate 2.12, CI 0.94–4.77,
P  .07). For adults, relapse rates (pooled estimate 0.86, CI 0.62–
1.19), transplant related mortality (pooled estimate 1.04, CI 0.52–
2.08) and disease free survival (pooled estimate 0.59, CI 0.18–1.96)
were not statistically different. In conclusion, pooled analysis of
comparative studies in children and adults revealed that 1-2 anti-
gens mismatched UCBT had consistently equivalent survival out-
comes when compared with fully matched unrelated donor BMT.
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UNMANIPULATED HLA 2-3 ANTIGEN-MISMATCHED (HAPLOIDENTI-
CAL) NONMYELOABLATIVE STEM CELL TRANSPLANTATION
Ikegame, K.1, Fujioka, T.1, Taniguchi, Y.1, Yoshihara, S.1,
Kawakami, M.1, Hasei, H.1, Kaida, K.1, Masuda, T.1, Kim, E.H.1,
Kanakura, Y.1, Ogawa, H.1,2 1. Osaka University Graduate School of
Medicine, Suita, Osaka, Japan; 2. Hyogo College of Medicine, Nishi-
nomiya, Hyogo, Japan.
To expand the donor pool, allogeneic stem cell transplantation
(SCT) using HLA 2-3 antigen-mismatched (haploidentical) related
donors has been studied. To date, there are a few reports describ-
ing nonmyeloablative stem cell transplantation (NST) from HLA-
haploidentical donors. We recently showed that a nonmyeloabla-
tive regimen consisting of ﬂudarabine, busulfan, and ATG was
sufﬁciently immunosuppressive to achieve donor type engraftment
in transplantation from HLA-haploidentical donors who had 1
antigen-mismatch in the GVH direction and 2-3 antigen-mis-
matches in the HVG direction (Leukemia, 2003). In that study,
however, acute GVHD could not be sufﬁciently controlled with a
GVHD prophylaxis using cyclosporine or tacrolimus. We have
been testing a protocol for HLA-haploidentical NST from 2-3
antigen-mismatched donors in the GVH direction without T-cell
depletion using more intensiﬁed GVHD prophylaxis (tacrolimus
and methylprednisolone). Methods: We performed an HLA-hap-
loidentical NST from 2-3 antigen-mismatched donors in the GVH
direction. Between Jan 2000 and July 2005, 30 patients with he-
matologic malignancies, including AML, ALL, CML, and NHL,
underwent allogeneic SCT in Osaka University Hospital. The
median age of the patients was 50 (range 28–63). All patients
except for 3 patients with Philadelphia chromosome were in ad-
vanced stage at the time of transplantation. Four patients had a
prior autologous SCT, and all of them underwent HLA-hap-
loidentical NST because of recurrence of the original disease.
Preconditioning regimen consists of ﬂudarabine (30 mg/m2  6),
busulfan 4 mg/kg  2, and rabbit ATG (Fresenius) 2 mg/kg  4.
GVHD prophylaxis regimen consists of tacrolimus 0.02 mg/kg/day
and methylprednisolone 1 mg/kg/day from day 0. Results: All
patients except for one achieved donor type engraftment. The
patient who had a rejection was successfully rescued with second
transplantation from the same donor. Fifteen patients did not
develop acute GVHD clinically, and only 5 patients developed
grade II GVHD. The main causes of death were relapse and
thrombotic microangiopathy. The overall survival at 3 years was
49.2 % at a median follow-up of 664 days (range, 37–1918 days).
Conclusions: HLA-haploidentical NST may be feasible for pa-
tients who are at high risk and lack available donors, and who are
considered ineligible for myeloablative regimens because of ad-
vanced age or comorbidities, although our results have to be
conﬁrmed in a large-scale study.
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THE IMPACT OF HLA-B ALLELE LEVEL MATCHING ON UNRELATED
STEM CELL DONOR TRANSPLANTS IN GERMANY
Mueller, C.R.1, Hirv, K.2, Goldmann, S.F.2, Schwarz, K.2 1. ZKRD
Zentrales Knochenmarkspender-Register, Ulm, Germany; 2. RC BTS
Baden-Wu¨rttemberg-Hessen, Ulm, Germany.
The German Consensus for matching allogeneic donors of he-
matopoietic progenitor cell (1996/2000) recommends matching
donors for HLA-A,B on serological level (2 digit allele level match-
ing within split groups for B15, B40) and by allele level for DRB1
and, if possible, DQB1. We have retrospectively performed se-
quencing based HLA-A,B,C analyses for 262 adult unrelated donor
recipient pairs matching for A, B, and DRB1 according to the
above deﬁnition in order to see if outcome could be improved by
more stringent selection criteria. Accepted diagnoses were ALL
(21%), AML (39%), CML (33%), and MDS (7%). Sixty percent of
the patients were male with a median age of 38 (range 18–67)
whereas 67% of the donors were male with a median age of 36
(range 19–58). The patients were transplanted in Berlin (56),
Erlangen (6), Hannover (9), Heidelberg (18), Mainz (56), Munich
(50), Regensburg (13), Ulm (11), and Wiesbaden (43) using het-
erogeneous regimens for conditioning and GvHD-prophylaxis.
After analyzing the relevant covariates, we stratiﬁed the Cox pro-
portional hazard model for patient age ( 	 median), diagnosis,
and disease phase (early 145, advanced 117). We found 20 pairs
with an allele level difference for A, 43 for B, 112 for C, and 20 for
DQB1. The only signiﬁcant detrimental effect for survival was
seen for allele level differences of HLA-B with R  1.56 (1.01 . . .
2.41) and P  .05. The survival curves did not suggest an inﬂuence
of any other HLA difference mentioned except for advanced dis-
ease where allele differences of HLA-A or C may be beneﬁcial,
probably due to a GvL effect. Study supported by the German Jose´
Carreras Leukemia Foundation.
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